Printer Friendly Version View printer-friendly version
<< Back
Total Voting Rights
RNS Number : 7575P
Vernalis PLC
31 May 2018
 

TOTAL VOTING RIGHTS

 

VERNALIS PLC (the "Company")

 

31 May 2018

 

Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,830,515 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

 

The total number of voting rights in the Company is therefore 526,830,515.

 

The above figure of 526,830,515 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.

 

-  ends  -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 


Canaccord plc (Nominated Adviser and Joint Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 


Shore Capital (Joint Broker):

+44 (0)20 7408 4090

Mark Percy

Toby Gibbs

 


FTI Consulting (Financial Communications):

+44 (0) 20 3727 1000

Ben Atwell

Simon Conway

Stephanie Cuthbert

 


Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 


 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

 

For further information about Vernalis, please visit www.vernalis.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRURVBRWRAVOAR